Registration Dossier

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

Short description of key information on bioaccumulation potential result: 
No bioaccumulation based on study results.

Key value for chemical safety assessment

Bioaccumulation potential:
low bioaccumulation potential

Additional information

Following oral gavage, excretion of the test substance, Bemotrizinol, was rapid with 94 - 97% of administered dose (50 mg [14C]-CGF-C1607/kg) excreted directly in faeces within 96 hours as unchanged Bemotrizinol. Concentration levels in blood and plasma were below the limit of detection. Urinary excretion accounted for 0.1 - 0.3% of the dose and residual radioactivity in tissues and carcass accounted for 0.1 - 0.3% of the dose (CTL, 2002). In a 90 day repeated dose dermal study, measurements of plasma concentrations of the test item showed very low (ca. 0.01%) percutaneous absorption (CIT, 2004). In conclusion, the test substance has a very low potential for absorption via oral and dermal routes.

Absorption through the inhalation route depends on particle size when exposure relates to the solid state of the substance as a powder. The particle size distribution for bemotrizinol showed that 75% of the particles were between 90 and 125 µm. Less than 0.5% of the particles proved to be smaller than 10 µm, while 87% was > 90 µm. Particles of 100 μm or larger are not typically drawn into the body by inhalation because of their size. Particles in the size of range of 10 to 100 μm are unable to make the turns and impact on the nasal hairs, nasal mucosa, or mucus-covered ciliated epithelium in the bronchi and bronchioles. Hence, the particle size of bemotrizinol applied as a powder does not hold significant evidence for a hazard by inhalation.